In seven advanced NSCLC patients who developed EGFR TKI resistance, Yeo et al. performed molecular screening of both tumor (re-biopsy) and CTC samples by direct sequencing [143]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.